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implicated in the pathogenesis of both preterm labour and neonatal morbidity,
isease of prematurity (CLD), but despite numerous studies, reviews and meta-
analyses, its exact role remains unclear. Many papers call for a deﬁnitive randomised control trial to
determine if eradication of pulmonary Ureaplasma decreases the rates of CLD but few address in detail the
obstacles to an adequately powered clinical trial. We review the evidence for Ureaplasma as a causative agent
in CLD, asking why a randomised control trial has not been performed. We surveyed the opinions of senior
neonatologists in the UK on whether they felt that there was sufﬁcient evidence for Ureaplasma either
causing or not causing CLD and whether a deﬁnitive trial was needed, as well as their views on the design of
such a trial. Additionally, we ascertained current practice with respect to Ureaplasma detection in preterm
neonates in the UK. There is clear support for an adequately powered randomised controlled clinical trial by
senior neonatologists in the UK. There are no reasons why a deﬁnitive trial cannot be conducted especially as
the appropriate samples, and methods to culture or identify the organism by PCR are already available.
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The role of Ureaplasma in neonatal morbidity and mortality has
long been controversial and its role as a neonatal pathogen has been
studied and questioned since the late 1970s [1]. Ureaplasma spp. has
been implicated in the pathogenesis of both preterm labour and
neonatal morbidity, particularly chronic lung disease of prematurity
(CLD), but its exact role remains unclear. We review the evidence
especially asking why an adequately powered randomised controlCardiff University, Heath Park,
187; fax: +44 29 2074 4283.
r CC BY license.trial to determine the causative role of Ureaplasma in the pathogenesis
of CLD has not been performed.
2. Ureaplasma spp.
Ureaplasmas are eubacteria which belong to the class Mollicutes.
Theydonot have cellwalls and are thought to be the smallest free-living,
self-replicating cells. Theyare limitedby the lack of cellwall to a parasitic
existence in eukaryotic cells. Ureaplasmas were previously designated
“T-mycoplasma” but later the genusUreaplasmawas designated in view
of their use of urea as ametabolic substrate.Ureaplasma urealyticumwas
the only species known to infect humans and this species was recently
subdivided into 2 separate species, U. urealyticum and U. parvum, on the
basis of their 16S ribosomal RNA gene sequences.
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Up to 80% ofwomen have been reported to be colonisedwith genital
mycoplasmas [2]. Ureaplasma spp. has been shown to be implicated in
preterm labour, spontaneous abortion and still birth [1]. It has also been
recordedas themost commonorganism isolated from the amnioticﬂuid
ofwomen inpreterm labour, evenwith intactmembranes [3,4]. Asmany
as 22% of women with PROM or preterm labour have been shown to
have evidence of U. urealyticum in their amniotic ﬂuid [5].
Transmission of Ureaplasma from a colonised or infected mother
may depend on a number of variables: particularly gestation, birth-
weight, route of delivery and preterm prelabour rupture of the
membranes. Preterm infants appear to be more likely to become
colonised than their term counterparts [6] with the rate of vertical
transmission ranging between 18% and 55% for term infants and 29%
and 55% for preterm infants [7].
Theremay be a higher risk of vertical transmission ofUreaplasma in
babies of lower birth weight, for example in babies weighing b1000 g
at birth transmission may be up to 89% [8] but a transmission rate of
only 15% has been reported among infants of N1500 g birthweight [9].
Alfa et al. showed that very low birth weight (VLBW, b1500 g) infants
were at signiﬁcantly higher risk of acquiring Ureaplasma spp. in their
respiratory tract than larger preterm infants [6]. The underlying cause
of preterm delivery and mode of delivery have been shown to be
associated with Ureaplasma transmission to the newborn. Aaltonen et
al. [10] reported a series of 49 infants born at b30 weeks gestation, in
which 45% of 33 spontaneous deliveries were colonised with Urea-
plasma but none of the electively delivered infants appeared to be
colonised. Goldenberg et al. [11] also reported a higher prevalence ofU.
urealyticum orMycoplasma hominis in umbilical cord blood among 351
mother/baby pairs at 23–32 weeks where infants had delivered
spontaneously rather than electively. Infants with Ureaplasma are
more likely to have been born following preterm prelabour rupture of
membranes than those not colonised [12].
4. Ureaplasma in the newborn infant
Ureaplasma has been implicated in neonatalmorbidity andmortality
including congenital pneumonia, pretermdelivery, lowbirthweight and
intrauterine growth retardation [1] and it is thought to infect or colonise
up to 37%of newborns [13]. It has been implicated in the pathogenesis of
neonatal pneumonia and meningitis and there are also reports of a
systemic inﬂammatory response in babies with evidence of Ureaplasma
in the lower respiratory tract as evidenced by an elevated white blood
cell count, particularly in the ﬁrst 2 days of life [14,15].
There have been a number of case reports ofUreaplasma infection of
the cerebrospinal ﬂuid (CSF). Waites et al. [16] suggest that Ureaplasma
spp. may in fact be a relatively common cause of CSF infection in the
neonatal population. Their study, along with other case reports, records
a range of central nervous system clinical outcomes for infants inwhom
such an infection is diagnosed — from spontaneous resolution [17], to
development of hydrocephalus or intra-ventricular haemorrhage [18],
to mortality in associationwith erythromycin resistant Ureaplasma spp.
[19]. A single case report in 2002 [20] has also implicated Ureaplasma in
the formation of a brain abscess in a neonate.
Cultrera et al. [21] studied the relationship between neonatal
respiratory distress syndrome (RDS) and Ureaplasma in 50 babies of
b37 weeks gestation. Fifteen out of 24 babies with RDS had U.
urealyticum or U. parvum detected and only 4 of 26 babies without
RDS were colonised with either organism, thus suggesting that Urea-
plasma plays a role in the development of RDS. In contrast, Hannaford et
al. [22] showed signiﬁcantly decreased incidence of RDS in infants of
b28 weeks gestationwho were colonised with Ureaplasma but many of
the colonised infants progressed to develop CLD which is in keeping
with data from Watterberg's group showing an association between
chorioamnionitis and development of CLD [23].5. Chronic lung disease of prematurity
The association between the presence of Ureaplasma and the devel-
opment of CLD remains controversial and hotly debated. The pathogen-
esis of CLD is multi-factorial with prematurity, ventilator induced lung
injury, oxygen therapy, patent ductus arteriosus, ﬂuid balance and
infection, bothante- andpost-natal, all appearing tohave a role to play. It
is often difﬁcult to dissect out the effect of one particular risk factor as
there is overlap between the risk factors in this multi-factorial disease.
Pulmonary Ureaplasma colonisation is strongly linked to preterm
delivery and the question remains if this pulmonary colonisation with
Ureaplasma is an independent risk factor for CLD.
There have been numerous studies investigating the role of Urea-
plasma in the development of CLD, as well as many reviews and meta-
analyses published in recent years. The consistent observation in many
publications is the difﬁculty in interpreting evidence from available
studies due to small sample sizes, vastly different inclusion criteria,
differentmethods of sampling and testing, differentdiagnostic criteria for
various outcomes including CLD. Many call for deﬁnitive studies but few
address in detail the obstacles to an adequately powered clinical trial.
In 1995, a meta-analysis by Wang et al. included 1479 babies from
17 studies [24] reporting a signiﬁcant association between CLD
diagnosed at 28 days of life and Ureaplasma colonisation with an
overall relative risk of 1.72 (95% conﬁdence intervals 1.5–1.96). Many
studies at the time did not use a deﬁnition of oxygen dependency at
36 weeks to diagnose CLD thus associationwith this outcome was not
available.
Since that review, several further studies have been completed,
including one by Kotecha et al. [25] who sought Ureaplasma in
bronchoalveolar lavage ﬂuid from 17 preterm neonates without
clinical or laboratory evidence of infection in either the mother or
infant and reported that 6 were positive for U. urealyticum. Of the 6
babies with Ureaplasma, 5 developed CLD whereas only 4 of the 11
babies without Ureaplasma developed CLD. Their data strongly
implicated Ureaplasma in the development of the pulmonary inﬂam-
matory response observed in infantswho progress to develop CLD. In a
cohort of 126 preterm deliveries, Kafetzis et al. [9] found a signiﬁcant
increase in CLD as well as mortality among Ureaplasma colonised
infants. vanWaarde et al. [26] found that Ureaplasmawas signiﬁcantly
associated with both CLD and lower gestational age but logistic
regression analysis failed to show a correlation between Ureaplasma
colonisation and CLD. They highlight the need for correction for
gestation in this sort of study and note several studieswhich had found
signiﬁcant relationships between Ureaplasma and CLD where this
adjustment had not been made.
In 2005, a further meta-analysis by Schelonka et al. [27] including
23 studies and 2216 babies showed an odds ratio of 2.83 (95%
conﬁdence intervals 2.29–3.51) for the relationship between the
presence of Ureaplasma and CLD diagnosed at 28 days of life. There
were 751 babies for whom data was available regarding CLD at
36 weeks gestation, again this showed a signiﬁcant association.
However, they noted that studies with small numbers were more
likely to inﬂuence the association suggesting publication bias against
studies which perhaps did not show an association.
More recent studies continue to fuel the controversy: Pandey et al.
[12] reported no role for Ureaplasma in the development of CLD in a
group of 100 babies of b34 weeks gestation. Goldenberg et al. [11]
studied 351 mother/baby pairs at 23–32 weeks, where the umbilical
cord blood showed evidence of Ureaplasma or M. hominis and a
probable association of U. urealyticumwith the development of CLD. In
other studies, U. urealyticum colonised infants have shown a non-
signiﬁcant trend towards higher neonatal morbidity (longer ventila-
tion, longer hospital stay, younger gestational age, higher incidence of
CLD and more late onset sepsis) [5].
The role of Ureaplasma in CLD is further complicated by the identi-
ﬁcation of different patterns ofUreaplasma colonisation in the preterm
Fig. 1. Clinicians' opinion of whether Ureaplasma causes CLD or not.
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may also impact on the likelihood of a colonised neonate developing
CLD, with only the “persistently positive” group showing a higher rate
of CLD [28].
6. Obstacles to a clinical trial
The lack of an optimal sample and method of identiﬁcation of
Ureaplasma have perhaps contributed the most to the lack of an
adequately powered clinical trial to determine if eradication of Urea-
plasma decreases the rates of CLD. The optimal clinical sample for
detection of Ureaplasma infection or colonisation remains unclear.
Clinical samples reported in the literature vary from amniotic ﬂuid
[5,29] taken at antenatal amniocentesis through to cord blood [11] and
placental swabs or tissue [30–32] taken at delivery to gastric aspirates
at delivery or later endotracheal, bronchoalveolar and nasopharyngeal
samples [25,31] or even neonatal blood samples [21]. Some of the
contradictory ﬁndings in the literature may be as a result of different
sampling methods and different diagnostic tests being applied. Most
satisfactory samples are likely to be either tracheal ﬂuid or gastric ﬂuid
[33].
Similarly the best test to identify Ureaplasma is not entirely clear.
Traditional culturing techniques have been cumbersome but modern
techniques such as the polymerase chain reaction (with quantitation
by real time PCR) show great promise [34] especially after an initial
period of culture for 24–48 h. Our preliminary data has shown that
culture is required only for 24–48 h to identify the presence of Urea-
plasma in most infants. Subsequent use of PCR is mainly for epide-
miological and research purposes including identiﬁcation of the
serovar and mechanisms of antibiotic resistance.
7. Treatment of Ureaplasma for prevention of CLD
If Ureaplasma has a causative role in the pathogenesis of CLD, it
would be reasonable to expect the incidence of CLD to decrease by
eradicating its colonisation with antibiotic treatment. Erythromycin is
themost commonly used antibiotic for eradication of Ureaplasma [35],
although contradictory results of such treatment have been reported.
A 5–10 day course of treatment failed to eradicate Ureaplasma in 55%
of very low birthweight infants studied by Baier et al. [36] however, an
earlier study found almost all patients became culture negative after a
7–10 day course [37]. An additional important point is the lack of
information on antibiotic resistance of Ureaplasma to conventional
antibiotics used in neonatal practice.
Once again the literature contains a number of small sample size
studies which vary in the time of commencement of treatment, type
and duration of antibiotic therapy and many lack documentation of
eradication of the organism at the end of the course of treatment.
However, only two randomised controlled trials have been included
in the Cochrane review by Mabanta et al. [38] examining studies
investigating the treatment of Ureaplasma to decrease the rate of
CLD. In the ﬁrst study, Lyon et al. [39] treated infants prior to knowing
their colonisation status and showed no change in the number of
infants who developed CLD. In the second study, Jonsson et al. [40]
treated those infants with positive cultures from endotracheal or
nasopharyngeal samples and were able to show a reduction in
colonisation but not CLD. Together these two studies included only
37 colonised patients (clearly poorly powered to address the
underlying question of whether treatment of Ureaplasma can
decrease the rates of CLD) and there was no signiﬁcant reduction
in CLD with treatment in either study — disparate study designs
prevented the results from being combined in the meta-analysis.
Neither study reported any adverse effects of a 7–10 day course of
erythromycin.
Macrolides are of great interest, not only because of their anti-
microbial activities against Mollicutes such as Ureaplasma, but alsobecause of their anti-inﬂammatory actions acting via a variety of path-
ways [41]. Pharmacokinetics of erythromycin in preterm infants has
previously been published [37] and the mean inhibitory concentration
(MIC) for clinical isolates of Ureaplasma from isolated from newborn
infants has also been reported [42]. Interestingly Ballard and Shook have
also conductedapilot study to assess the feasibilityof azithromycin asan
anti-inﬂammatory [43].
8. Neonatologists' opinion on the role of Ureaplasma in the
development of CLD
Despite many papers studying the role of Ureaplasma in the patho-
genesis of CLD, it is perhaps surprising that an adequately powered
randomised control trial has not been performed [38]. Reasons behind
the lack of such a trial may include technical ones (e.g. the best sample,
culture techniques) or individual views of clinicians perhaps believing
that Ureaplasma does not cause respiratory disease in preterm newborn
infants. We therefore sought the views of senior clinicians in the United
Kingdom(UK) caring fornewborn infants indedicatedneonatal units. In
particular, we were interested if they thought, from their own reading,
that there was sufﬁcient evidence of Ureaplasma causing or not causing
CLD, and if they had views on thenecessity of a deﬁnitive but sufﬁciently
powered randomised control trial to determine if eradication of Urea-
plasma decreases the rates of CLD.
9. Survey method
We designed a structured questionnaire consisting of 18 questions
each with a choice of possible answers and mailed it to 300 UK
consultant neonatologists or paediatricians with a special interest in
neonatology. A second reminder was sent to those who did not reply
within 4–6 weeks.
Fig. 2. Clinician estimates of colonisation with Ureaplasma in infants born at less than
28 weeks gestation.
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• Their opinion of the current evidence for Ureaplasma causing or not
causing CLD
• Their own current practice for detecting Ureaplasma
• If in their opinion a deﬁnitive trial to determine “if Ureaplasma spp.
causes CLD” was necessary?
• Their views on the design of a trial.
10. Survey results
Of the 300 questionnaires sent out,172 (57%) were returned. Of the
172 respondents, 137 were consultant neonatologists while the
remainder were paediatricians with a special interest in neonatalFig. 3. Whether clinicians routinely tested or would be interested in an affordable test
for identifying Ureaplasma.medicine. One hundred and twenty ﬁve stated that they worked in
level 3 intensive care unit and only 7 worked in level 1 units.
Questionnaireswere sent to clinicians in 97 different neonatal units. Of
these, a responsewas received from at least one consultant in 82 units.
The units fromwhich no responses were received included six level 1
units, seven level 2 units and two level 3 units. Thus the majority of
neonatal units doing intensive care responded and most level 1 and 2
units also responded from the majority of units. When analysed
separately therewere no particular differences of opinion between the
staff from units providing differing level of intensive care.
When asked if they thought there was enough evidence showing if
Ureaplasma caused CLD, of those who gave an opinion, 12 (10% of those
with an opinion) thought there was but the majority did not (104, 90%)
with the remainder being undecided (Fig. 1A). Interestingly, 125 (of 132
with an opinion, 95%) did not think there was sufﬁcient evidence that
Ureaplasmadidnot causeCLDwithonly7(5%) thinking therewas (Fig.1B).Fig. 4. Frequency of local testing and nature of sample sent for identifying Ureaplasma as
well as how often Ureaplasma is seen in their own units.
Fig. 5. Clinicians' opinion ofwhat drug should be used in a clinical trial to test if eradication
of Ureaplasma decreases the rates of CLD.
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infants of b28weeks gestation,most neonatologists estimated between
5 and 25% (range 0–90%, mode 20%) (Fig. 2). This estimate was unlikely
to have been based on personal clinical experience as only 21% of
neonatal units reported testing for Ureaplasma either often or routinely
(N3 samples/year) (Fig. 3A). Although our questionnaire did not spe-
ciﬁcally explore the reasons for the low rate of testing for Ureaplasma,
many respondents added free text stating that testing for Ureaplasma
was either too expensive or that the culture results were often delayed
thus not being useful in clinical practice. It was therefore interesting to
note that 102 of 122 (84%) who gave a response (with 50 undecided)
would be interested in an affordable test to identify the organism
(Fig. 3B).
Of the 102 respondents who tested for Ureaplasma, the sample type
varied widely as did the timing of the sampling. As the evidence for the
role of Ureaplasma in the development of CLD remains uncertain, it is
perhaps not surprising that samples were sent for testing according to
the clinical status of the infant rather than an expectation of the sample
being positive (Fig. 4A). Unsurprisingly, endotracheal secretions were
the most frequent sample sent for testing but others including blood
culture were also sent by some units (Fig. 4B). Many units sent more
than one sample type.
Only a few respondents were able to estimate the number of
infections seen by their own unit (28%) with most saying they were
unable to answer the question due to lack of routine testing (Fig. 4C).
Many respondents stated that they did not test forUreaplasma because a
speciﬁc test was not available locally from their local microbiology
service and that results were not readily available if sent to regional or
supra-regional laboratories. They clearly suggested that the results
should be available within a reasonable time and should be affordable.
Having ascertained current practice, we proceeded to seek opinion
of whether a deﬁnitive randomised trial to formally assess the role of
Ureaplasma in the development of CLD was thought necessary. From
the 135 who gave an opinion, 117 (87%) thought that a clinical trial
was necessary but 37 did not register an opinion. From 79 who had an
opinion (with 38 undecided), 76 (96%) stated that they would be
interested in participating in a future clinical trial.
Themajority (90/117)of respondentswhowere in favourof a clinical
trial suggested that infants between 23 and 28 weeks gestation should
be included in a trial and that erythromycin was their drug of choice
within a trial (Fig. 5). Currently in the UK erythromycin is readily
available for neonatal use in both intravenous (IV) and oral formulations
whereas azithromycin is only available as an oral preparation (although
available as an intravenous preparation in the US) and experience with
clarithromycin in the newborn is limited.
As far as the timing of commencing antibiotic treatment was
concerned, there was an equal divide between those who wanted to
wait for culture results before starting treatment and those whothought that treatment should start immediately at birth. Many
suggested starting early as the inﬂammatory process would have been
ﬁrmly established by the time culture results were available.
The duration of treatment favoured by UK neonatologists was 7–
14 days (range 3–28 days, mode 14 days) and when asked if they had
any concerns with antibiotic treatment, 51 were concerned, 55 were
not and 11 were unsure. Concerns, when registered, were mainly
about gastrointestinal effects particularly with erythromycin; anti-
biotic resistance; alterations to normal microbial ﬂora or phlebitis in
the smallest preterm infants.
11. Conclusions
Despite many studies investigating the role of Ureaplasma in the
development of CLD, controversy continues partly due to the lack of an
adequate clinical trial to conﬁrm or refute the association. Repeated
meta-analyses implicate the association between Ureaplasma and CLD
but the Cochrane review [38] could only include two very disparate
studies with very small numbers stating that even a large effect would
have been missed by the trials included. There is clear support for a
clinical trial at least by senior neonatologists in the UK. There are no
reasons why a deﬁnitive trial cannot be conducted especially as the
appropriate samples (endotracheal or gastric ﬂuid) and methods to
culture or identify the organism by PCR are already available.
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